News Madrigal eyes combination MASH therapy with Pfizer deal Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.
News Madrigal closes on EU approval of first MASH treatment Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
News Madrigal Pharma is first over the MASH finish line Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that ha
News Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
